MetaCap

Exelixis (EXEL) vs Neurocrine Biosciences (NBIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Exelixis (EXEL) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 52.0% versus a gain of 6.2%. Over five years, EXEL leads with a +278.8% price change compared with +73.1% for NBIX. Exelixis is the larger company by market cap ($15.77 billion vs $15.24 billion), about 1.0 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +7.0%).

On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.2x vs 15.1x for Exelixis). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 16.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EXEL+52.03%NBIX+6.16%
+75%+29%-17%
Nov 21, 20251 yearNov 20, 2026
EXEL+258.46%NBIX+75.04%
+301%+136%-30%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EXEL versus NBIX key metrics
MetricEXELNBIX
Share price$64.63$150.57
Market cap$15.77B$15.24B
1-day change-1.82%-3.84%
YTD return+47.46%+6.16%
1-year return+52.03%+6.16%
5-year return+278.84%+73.11%
P/E ratio (TTM)19.3522.34
Forward P/E15.1212.24
EPS (TTM)$3.34$6.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.32B$2.86B
Revenue growth (YoY)+6.98%+21.45%
Net income (latest FY)$782.57M$478.60M
Gross margin96.39%98.18%
Operating margin37.59%21.64%
Net margin33.73%16.73%
52-week high$73.69$186.12
52-week low$39.71$122.14
Distance from 52-week high-12.29%-19.10%
Analyst consensusbuystrong_buy
Avg. price target upside-4.73%+38.50%
Average volume2.45M1.34M
Shares outstanding244.01M101.22M
Employees1,0772,500
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EXEL has outperformed NBIX by 45.9 percentage points over the past year.
  • Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
  • Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +6.98%).

About Exelixis

EXEL stock →

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees

About Neurocrine Biosciences

NBIX stock →

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees

EXEL vs NBIX FAQ

Which is bigger, Exelixis or Neurocrine Biosciences?

Exelixis (EXEL) is larger, with a market capitalization of $15.77B compared with $15.24B for Neurocrine Biosciences (NBIX).

Which stock has performed better over the past year, EXEL or NBIX?

EXEL returned +52.03% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, EXEL or NBIX?

EXEL has the lower trailing P/E at 19.4, versus 22.3 for NBIX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Exelixis and Neurocrine Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons